SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:liu-46244"
 

Sökning: onr:"swepub:oai:DiVA.org:liu-46244" > A randomized phase ...

A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer

Glimelius, B., (författare)
Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, SE-751 85 Uppsala, Sweden, Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
Sorbye, H., (författare)
Sørbye, H., Department of Oncology, Haukeland University Hospital, Bergen, Norway
Balteskard, L., (författare)
Department of Oncology, University Hospital, Tromsö, Norway
visa fler...
Bystrom, P., (författare)
Byström, P., Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
Pfeiffer, P., (författare)
Department of Oncology, University Hospital, Odense, Denmark
Tveit, K., (författare)
Department of Oncology, Ullevål University Hospital, Oslo, Norway
Heikkila, R., (författare)
Heikkilä, R., Department of Hemato-Oncology, Stavanger University Hospital, Stavanger, Norway
Keldsen, N., (författare)
Department of Oncology, Central Hospital, Herning, Denmark
Albertsson, M., (författare)
Department of Oncology, University Hospital, Malmö, Sweden
Starkhammar, Hans, (författare)
Linköpings universitet, Hälsouniversitetet, Linköpings universitet, Onkologi, Östergötlands Läns Landsting, Onkologiska kliniken US
Garmo, H., (författare)
Regional Oncologic Center, Uppsala, Sweden
Berglund, A., (författare)
Berglund, Å., Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, SE-751 85 Uppsala, Sweden
visa färre...
2008
Engelska.
Ingår i: Annals of Oncology. - 0923-7534 .- 1569-8041. ; 19:5, s. 909-914
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • <p>Background: To compare irinotecan with the Nordic 5-fluorouracil (5-FU) and folinic acid (FA) bolus schedule [irinotecan 180 mg/m2 on day 1, 5-FU 500 mg/m2 and FA 60 mg/m2 on day 1 and 2 (FLIRI)] or the Lv5FU2 schedule [irinotecan 180 mg/m2 on day 1, FA 200 mg/m2, 5-FU bolus 400 mg/m2 and infused 5-FU 600 mg/m2 on day 1 and 2 (Lv5FU2-IRI)] due to uncertainties about how to administrate 5-FU with irinotecan. Patients and methods: Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI. Primary end point was progression-free survival (PFS). Results: Patient characteristics were well balanced. PFS did not differ between groups (median 9 months, P = 0.22). Overall survival (OS) was also similar (median 19 months, P = 0.9). Fewer objective responses were seen in the FLIRI group (35% versus 49%, P = 0.001) but the metastatic resection rate did not differ (4% versus 6%, P = 0.3). Grade 3/4 neutropenia (11% versus 5%, P = 0.01) and grade 2 alopecia (18% versus 9%, P = 0.002) were more common in the FLIRI group. The 60-day mortality was 2.4% versus 2.1%. Conclusions: Irinotecan with the bolus Nordic schedule (FLIRI) is a convenient treatment with PFS and OS comparable to irinotecan with the Lv5FU2 schedule. Neutropenia and alopecia are more prevalent, but both regimens are equally well tolerated. © The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.</p>

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  (hsv//swe)
MEDICAL AND HEALTH SCIENCES  (hsv//eng)

Nyckelord

5-fluorouracil
Chemotherapy
Colorectal cancer
Irinotecan
Randomized trial
MEDICINE
MEDICIN

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy